PMID- 35684937
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20220716
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 28
DP  - 2022 Jun 10
TI  - Association Between Serum Homocysteine Levels and Severity of Diabetic Kidney 
      Disease in 489 Patients with Type 2 Diabetes Mellitus: A Single-Center Study.
PG  - e936323
LID - 10.12659/MSM.936323 [doi]
AB  - BACKGROUND This study from a single center aimed to investigate the association 
      between serum homocysteine (Hcy) levels and severity of diabetic kidney disease 
      (DKD) in 489 patients with type 2 diabetes mellitus (T2DM). MATERIAL AND METHODS 
      A total of 1163 patients with T2DM, including 674 T2DM without kidney disease 
      (T2DM group) and 489 T2DM with DKD (DKD group), were evaluated. The DKD group was 
      subdivided according to the chronic kidney disease (CKD) and albuminuria staging 
      criteria in "Kidney Disease: Improving Global Outcomes 2012 clinical practice 
      guideline" to quantify the severity of DKD: CKD stage 1 (n=164), CKD stage 2 
      (n=103), CKD stage 3 (n=95), CKD stage 4 (n=71), and CKD stage 5 (n=56) and stage 
      A1 (n=57), stage A2 (n=250), and stage A3 (n=182), respectively. Peripheral blood 
      was collected after 8 hours of fasting to test Hcy levels. RESULTS In CKD stages, 
      Hcy levels gradually increased with increasing DKD severity (CKD stage 1 to 5); 
      while in albuminuria stages, Hcy levels did not gradually increase with 
      increasing DKD severity (stage A1 to A3). Hcy was an independent risk factor for 
      CKD stages 2-5 (P<0.05), and had no effect on the albuminuria stages (P>0.05), 
      while it may indirectly affect the occurrence of albuminuria stages through its 
      impact on estimated glomerular filtration rate. CONCLUSIONS The relationship 
      between Hcy level and DKD severity was related to the different staging methods 
      used. Hcy was an independent risk factor for CKD stages but not albuminuria 
      stages.
FAU - Wu, Juan
AU  - Wu J
AD  - Department of Endocrinology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, China (mainland).
FAU - Liu, Dengke
AU  - Liu D
AD  - Department of Endocrinology, The Second Affiliated Hospital of Nanchang 
      University, Ganzhou, Jiangxi, China (mainland).
AD  - Department of Endocrinology, The First Affiliated Hospital of Gannan Medical 
      University, Ganzhou, Jiangxi, China (mainland).
FAU - Yang, Liu
AU  - Yang L
AD  - Department of Endocrinology, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, Hubei, China (mainland).
FAU - Liu, Jianping
AU  - Liu J
AD  - Department of Endocrinology, The The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20220610
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Albuminuria/complications
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Diabetic Nephropathies
MH  - Homocysteine
MH  - Humans
MH  - *Renal Insufficiency, Chronic/complications
PMC - PMC9195638
COIS- Conflict of interest: None declared
EDAT- 2022/06/11 06:00
MHDA- 2022/06/14 06:00
PMCR- 2022/06/10
CRDT- 2022/06/10 01:28
PHST- 2022/06/10 01:28 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
PHST- 2022/06/10 00:00 [pmc-release]
AID - 936323 [pii]
AID - 10.12659/MSM.936323 [doi]
PST - epublish
SO  - Med Sci Monit. 2022 Jun 10;28:e936323. doi: 10.12659/MSM.936323.